BioCardia Inc
BCDA
View Detailed Chart
1.270USD
-0.010-0.78%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
13.47MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.78%
5 Days
-12.41%
1 Month
-0.78%
6 Months
-38.94%
Year to Date
-41.74%
1 Year
-35.53%
View Detailed Chart
TradingKey Stock Score of BioCardia Inc
Currency: USD Updated: 2025-12-19Key Insights
BioCardia Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 177/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioCardia Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
15.500
Target Price
+983.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioCardia Inc Highlights
StrengthsRisks
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 58.00K.
Fairly Valued
The company’s latest PE is -0.90, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 96.50K shares of this stock.
BioCardia Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioCardia Inc Info
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Ticker SymbolBCDA
CompanyBioCardia Inc
CEOAltman (Peter)
Websitehttps://www.biocardia.com/
FAQs
What is the current price of BioCardia Inc (BCDA)?
The current price of BioCardia Inc (BCDA) is 1.270.
What is the symbol of BioCardia Inc?
The ticker symbol of BioCardia Inc is BCDA.
What is the 52-week high of BioCardia Inc?
The 52-week high of BioCardia Inc is 3.200.
What is the 52-week low of BioCardia Inc?
The 52-week low of BioCardia Inc is 1.000.
What is the market capitalization of BioCardia Inc?
The market capitalization of BioCardia Inc is 13.47M.
What is the net income of BioCardia Inc?
The net income of BioCardia Inc is -7.95M.
Is BioCardia Inc (BCDA) currently rated as Buy, Hold, or Sell?
According to analysts, BioCardia Inc (BCDA) has an overall rating of Buy, with a price target of 15.500.
What is the Earnings Per Share (EPS TTM) of BioCardia Inc (BCDA)?
The Earnings Per Share (EPS TTM) of BioCardia Inc (BCDA) is -1.414.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
